VERACYTE, INC.VCYTEarnings & Financial Report
Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.
Revenue
$114.4M
Gross Profit
$77.9M
Operating Profit
$4.6M
Net Profit
$5.7M
Gross Margin
68.1%
Operating Margin
4.0%
Net Margin
5.0%
YoY Growth
26.7%
EPS
$0.07
VERACYTE, INC. Q2 FY2024 Financial Summary
VERACYTE, INC. reported revenue of $114.4M (up 26.7% YoY) for Q2 FY2024, with a net profit of $5.7M (up 168.2% YoY) (5.0% margin). Cost of goods sold was $36.5M, operating expenses totaled $73.3M.
Key Financial Metrics
| Total Revenue | $114.4M |
|---|---|
| Net Profit | $5.7M |
| Gross Margin | 68.1% |
| Operating Margin | 4.0% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
VERACYTE, INC. Q2 FY2024 revenue of $114.4M breaks down across 3 segments, led by Testing at $107.0M (93.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Testing | $107.0M | 93.5% |
| Biopharmaceutical And Other | $3.6M | 3.1% |
| Biopharmaceutical And Other Contract Manufacturing And Testing | $1.9M | 1.6% |
VERACYTE, INC. Revenue by Segment — Quarterly Trend
VERACYTE, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Testing and Biopharmaceutical And Other) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Testing | — | $135.8M | $127.8M | $122.3M |
| Biopharmaceutical And Other | — | $686.0K | — | — |
| Biopharmaceutical And Other Contract Manufacturing And Testing | — | — | — | $1.7M |
VERACYTE, INC. Annual Revenue by Year
VERACYTE, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $517.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $517.1M |
| 2024 | $445.8M |
| 2023 | $361.1M |
| 2022 | $296.5M |
VERACYTE, INC. Quarterly Revenue & Net Profit History
VERACYTE, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $139.1M | +21.5% | $28.7M | 20.6% |
| Q4 FY2025 | $140.6M | +18.5% | $41.1M | 29.3% |
| Q3 FY2025 | $131.9M | +13.8% | $19.1M | 14.5% |
| Q2 FY2025 | $130.2M | +13.8% | $-980.0K | -0.8% |
| Q1 FY2025 | $114.5M | +18.2% | $7.0M | 6.2% |
| Q4 FY2024 | $118.6M | +20.8% | $5.1M | 4.3% |
| Q3 FY2024 | $115.9M | +28.6% | $15.2M | 13.1% |
| Q2 FY2024 | $114.4M | +26.7% | $5.7M | 5.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.4M | $115.9M | $118.6M | $114.5M | $130.2M | $131.9M | $140.6M | $139.1M |
| YoY Growth | 26.7% | 28.6% | 20.8% | 18.2% | 13.8% | 13.8% | 18.5% | 21.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.23B | $1.28B | $1.30B | $1.32B | $1.34B | $1.37B | $1.41B | $1.44B |
| Liabilities | $101.8M | $99.0M | $124.1M | $120.5M | $123.0M | $110.1M | $96.4M | $92.0M |
| Equity | $1.13B | $1.18B | $1.18B | $1.19B | $1.22B | $1.26B | $1.31B | $1.34B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $29.6M | $30.0M | $24.5M | $5.4M | $33.6M | $44.8M | $52.6M | $35.2M |